Andres Ricaurte Fajardo on CVT Experience from a Latin American Cohort
Andres Ricaurte Fajardo, Neurology resident at Pontificia Universidad Javeriana, shared on LinkedIn:
”Proud to share our latest article in the Journal of Stroke and Cerebrovascular Diseases:
“Clinical characterization and predictors of poor outcome in patients with cerebral venous thrombosis: Experience from a Latin American cohort.”
This study, conducted at Hospital Universitario San Ignacio (Bogotá, Colombia), provides one of the largest Latin American datasets of cerebral venous thrombosis (CVT) to date — highlighting regional risk patterns, imaging features, and outcome predictors in a high-altitude, low- and middle-income setting.
Key take-home messages
1. Headache remains the hallmark presentation — often mimicking migraine — emphasizing the need for high clinical suspicion even in isolated headache cases.
2. Anemia emerged as an independent predictor of poor in-hospital outcome, underscoring the role of systemic factors in CVT prognosis.
3. Venous infarction and subarachnoid hemorrhage were strong radiological predictors of poor functional recovery.
4. The CVT Risk Score showed external validity in this Latin American cohort, supporting its use for bedside triage.
5. These findings advocate for context-adapted risk stratification and management strategies tailored to LMIC environments.
6. Active malignancy was present in 12% of cases — reinforcing the intersection between cancer and cerebral thrombosis, a relationship increasingly recognized in neuro-oncology and systemic disease.
Grateful to my amazing co-authors and mentors from Pontificia Universidad Javeriana for this collaborative effort toward advancing stroke research in Latin America.”
Read the full article here.
Article: Clinical characterization and predictors of poor outcome in patients with cerebral venous thrombosis: Experience from a Latin American cohort
Authors: Andres Felipe Cardenas-Cruz, Andres Ricaurte-Fajardo, Silvia Andrade, Carlos Alvarado-De la Hoz, Isabel Torres-Camacho, Elkin Garcia-Cifuentes, Maria Paula Ardila, Betty Arevalo, Carlos Beltran, Laura Monsalve, Luis Roa-Wandurraga, Juliana Coral-Casas
Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Oct 27, 2025, 05:47Ahmed Koriesh on The Novel Approach in Use of Tenecteplase
-
Oct 27, 2025, 04:42Louise Breslin: Exciting Results in The CRYPTICS Trial
-
Oct 26, 2025, 16:55ECTH 2025: 3 Unforgettable Days of Science and Shared Purpose
-
Oct 26, 2025, 16:35Ahmed Koriesh on Thrombolysis in Stroke Patients on DOACs
-
Oct 26, 2025, 15:39Lisa Murphy on Life After Stroke Sessions at WSC 2025
-
Oct 27, 2025, 08:01Acquired Hemophilia A (AHA) is Rare and Often Missed - RPTH Journal
-
Oct 27, 2025, 05:00Wolfgang Miesbach on WFH Guidelines Covering FDA/EMA-Approved AAV Gene Therapy for Hemophilia
-
Oct 26, 2025, 15:04Nita Radhakrishnan and Colleagues on Inherited Haematological Conditions
-
Oct 26, 2025, 14:55Anirban Sen Gupta on Biosynthetic Blood Surrogates Current State-of-Art
-
Oct 26, 2025, 12:24Jean Philippe Galanaud, Jean Pierre Laroch, and Marc Righini on Historical Treatments of DVT
-
Oct 25, 2025, 07:42Adithya Hande: India’s Silent Killer and a Scientific Breakthrough
-
Oct 23, 2025, 09:57Arun V. J: Artificial Blood Is Closer Than You Think
-
Oct 23, 2025, 07:11Sebastien Lobet Presented the ACTIVLIM-Hemo Scale
-
Oct 23, 2025, 07:05Syed Ehsan Shah on Advantages of Werfen HemoCell Automation
-
Oct 22, 2025, 08:25Johanna Nystedt: Not Every Day We Can Release a New Blood Product to Meet An Unmet Medical Need!
-
Oct 27, 2025, 08:00Rohit Gosain: Revumenib is Now FDA Approved for R/R AML with NPM1 Mutation
-
Oct 27, 2025, 06:30Andres Ricaurte Fajardo on CVT Experience from a Latin American Cohort
-
Oct 27, 2025, 05:15Love Preet Kalra: I Had The Pleasure of Meeting Future Leader Sarah Matuja
-
Oct 25, 2025, 09:32Sylaja Pn Wins 2025 WSO Presidential Award
-
Oct 25, 2025, 08:21Courtney Lawrence: Listen. Empower. Deliver. Save Lives!